DK3463422T3 - Sammensætninger og fremgangsmåder til behandling af stofskiftelidelser - Google Patents

Sammensætninger og fremgangsmåder til behandling af stofskiftelidelser Download PDF

Info

Publication number
DK3463422T3
DK3463422T3 DK17805843.4T DK17805843T DK3463422T3 DK 3463422 T3 DK3463422 T3 DK 3463422T3 DK 17805843 T DK17805843 T DK 17805843T DK 3463422 T3 DK3463422 T3 DK 3463422T3
Authority
DK
Denmark
Prior art keywords
compositions
methods
metabolic disorders
treating metabolic
treating
Prior art date
Application number
DK17805843.4T
Other languages
Danish (da)
English (en)
Inventor
Hongli Liu
Original Assignee
Shanghai Hep Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shanghai Hep Pharmaceutical Co Ltd filed Critical Shanghai Hep Pharmaceutical Co Ltd
Application granted granted Critical
Publication of DK3463422T3 publication Critical patent/DK3463422T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/162Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021Intradermal administration, e.g. through microneedle arrays or needleless injectors
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00Reverse transcribing DNA viruses
    • C12N2730/00011Details
    • C12N2730/10011Hepadnaviridae
    • C12N2730/10111Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10122New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00Reverse transcribing DNA viruses
    • C12N2730/00011Details
    • C12N2730/10011Hepadnaviridae
    • C12N2730/10111Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10133Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Diabetes (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
DK17805843.4T 2016-05-30 2017-05-31 Sammensætninger og fremgangsmåder til behandling af stofskiftelidelser DK3463422T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201610370442 2016-05-30
PCT/CN2017/086558 WO2017206898A1 (en) 2016-05-30 2017-05-31 Compositions and methods for treating metabolic diseases

Publications (1)

Publication Number Publication Date
DK3463422T3 true DK3463422T3 (da) 2024-07-22

Family

ID=60479717

Family Applications (1)

Application Number Title Priority Date Filing Date
DK17805843.4T DK3463422T3 (da) 2016-05-30 2017-05-31 Sammensætninger og fremgangsmåder til behandling af stofskiftelidelser

Country Status (10)

Country Link
US (2) US11633454B2 (https=)
EP (1) EP3463422B1 (https=)
JP (1) JP7684788B2 (https=)
KR (1) KR102627084B1 (https=)
CN (1) CN109310737B (https=)
AU (1) AU2017274094B2 (https=)
CA (1) CA3026140A1 (https=)
DK (1) DK3463422T3 (https=)
ES (1) ES2979305T3 (https=)
WO (1) WO2017206898A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022145711A1 (ko) * 2020-12-28 2022-07-07 주식회사 엠디헬스케어 마이크로코커스 루테우스 유래 세포외 소포를 포함하는 대사질환 예방 또는 치료용 조성물
KR102605753B1 (ko) * 2021-08-06 2023-11-29 주식회사 동운아나텍 인공지능 기반의 혈당 예측 시스템 및 방법
CN116621944A (zh) * 2022-02-10 2023-08-22 成都奥达生物科技有限公司 一种长效肝炎病毒进入抑制剂

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102675430B (zh) * 2005-08-12 2014-08-27 上海贺普药业股份有限公司 乙型肝炎病毒表面l蛋白相关肽
CN104130316B (zh) * 2005-08-12 2017-04-19 上海贺普药业股份有限公司 乙型肝炎病毒表面l蛋白相关肽
CN102241744B (zh) * 2010-05-14 2015-03-04 上海贺普药业股份有限公司 一种病毒感染阻断剂、其药物组合物及其应用
CN104781274B (zh) * 2012-11-12 2020-03-06 海德堡吕布莱希特-卡尔斯大学 用于治疗肝脏疾病和心血管疾病的脂肽
MX383664B (es) 2012-12-27 2025-03-14 Ngm Biopharmaceuticals Inc Uso de un péptido para modular la homeostasis de los ácidos biliares o tratamiento de una enfermedad relacionada con los ácidos biliares.
CN107106686B (zh) * 2014-10-07 2022-09-27 Myr有限公司 Hbv和hdv感染的联合治疗
EP3189850A1 (en) * 2015-12-16 2017-07-12 Ruprecht-Karls-Universität Heidelberg Liver targeting of cyclic pres-derived peptides of hbv
EP3181146A1 (en) * 2015-12-16 2017-06-21 Ruprecht-Karls-Universität Heidelberg Cyclic ntcp-targeting peptides and their uses as entry inhibitors

Also Published As

Publication number Publication date
KR102627084B1 (ko) 2024-01-19
AU2017274094B2 (en) 2020-09-10
AU2017274094A1 (en) 2019-02-14
CN109310737B (zh) 2023-05-05
US20230414706A1 (en) 2023-12-28
EP3463422A1 (en) 2019-04-10
EP3463422A4 (en) 2020-02-26
KR20190015392A (ko) 2019-02-13
US20200323951A1 (en) 2020-10-15
ES2979305T3 (es) 2024-09-25
US11633454B2 (en) 2023-04-25
JP7684788B2 (ja) 2025-05-28
JP2019520341A (ja) 2019-07-18
CA3026140A1 (en) 2017-12-07
EP3463422B1 (en) 2024-05-22
WO2017206898A1 (en) 2017-12-07
CN109310737A (zh) 2019-02-05

Similar Documents

Publication Publication Date Title
IL287952A (en) Compositions and methods for non-myeloablative conditioning
DK3212226T3 (da) Sammensætninger og anvendelsesfremgangsmåder til behandling af metaboliske lidelser
DK3206493T3 (da) Sammensætninger og fremgangsmåder til behandling af cns-forstyrrelser
DK3250210T3 (da) Sammensætninger og fremgangsmåder til behandling af cns-forstyrrelser
DK3386518T3 (da) Metoder og sammensætninger til behandling af en serpinc1-associeret forstyrrelse
DK3102673T3 (da) Fremgangsmåder og sammensætninger til behandling af beta-talassæmi
DK3185876T3 (da) Sammensætninger og fremgangsmåder til behandling af neurologiske lidelser
DK3119797T3 (da) Raav-baserede sammensætninger og fremgangsmåder til behandling af amyotrofisk lateralsklerose
DK3433266T3 (da) Fremgangsmåder til behandling af mitokondrieforstyrrelser
DK3206497T3 (da) Sammensætninger og fremgangsmåder til behandling af meibomsk kirtel-dysfunktion
DK3134130T3 (da) Sammensætninger og fremgangsmåder til behandling af hæmoglobinopatier
DK3137605T3 (da) Sammensætninger og fremgangsmåder til modulering af angiopoietin-lignende-3-ekspression
DK3394259T3 (da) Sammensætninger og fremgangsmåder til reducering af tau-ekspression
DK3484469T3 (da) Sammensætninger og fremgangsmåder til potentiering af antimikrober
DK3200815T3 (da) Fremgangsmåder og sammensætninger til behandling af cancer
DK3519572T3 (da) Forbindelser og fremgangsmåder til reduktion af tau-ekspression
DK3277270T3 (da) Sammensætninger og fremgangsmåder til behandling af anæmi
DK3242947T3 (da) Genterapi og elektroporese til behandling af maligniteter
DK3189074T3 (da) Sammensætninger og metoder til behandling og forebyggelse af inflammation
DK3347015T3 (da) Fremgangsmåder til diagnosticering og behandling af adfærdsforstyrrelser
DK3081263T3 (da) Sammensætninger og redskaber til behandling af glaukom
DK3524255T3 (da) Sammensætning til behandling af acne
DK3393655T3 (da) Fenfluramin-sammensætninger og fremgangsmåder til fremstilling af samme
DK3328864T3 (da) Terapeutiske forbindelser og sammensætninger til behandling af sociale forstyrrelser og stofmisbrugsforstyrrelser
DK3110446T3 (da) Fremgangsmåder og sammensætninger til behandling af Siglec-8-associerede sygdomme